{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:44Z","timestamp":1793821724558,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After curative-intent pancreatectomy for pancreatic ductal adenocarcinoma (PDAC), disease recurrence occurs almost invariably. Evidence guiding treatment of recurrence remains limited and may differ across single-site recurrence patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Scopus, MEDLINE, and the Cochrane Library were systematically searched for observational studies of adults with recurrent PDAC reporting liver-only, lung-only, or locoregional recurrence and post-recurrence treatments. Hazard ratio (HR) meta-analyses were performed to compare survival outcomes between treatment strategies for each recurrence location with additional descriptive survival summaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The inclusion criteria were met by 22 studies, with 17 included in the quantitative synthesis. Pattern-specific analyses favored selected local therapies. For liver-only recurrence, local therapy was associated with longer overall survival than chemotherapy alone (HR 0.26, 95% confidence interval [CI] 0.14\u20130.49), mainly due to surgical resection (HR 0.18; 95% CI 0.11\u20130.31). Ablation did not reach statistical significance. In lung-only recurrence, surgical resection was associated with longer survival than conventional management (HR 0.35; 95% CI 0.26\u20130.48). For locoregional recurrence, resection was associated with longer survival (HR 0.52; 95% CI 0.38\u20130.72). Stereotactic body radiotherapy outcomes from three small series were summarized descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma recurrence outcomes differ significantly by recurrence pattern. Across liver-only, lung-only, and locoregional recurrence, selected patients undergoing local therapy had longer survival than those managed conventionally. Although current observational data do not confirm broad efficacy for specific methods, these results support recurrence pattern-specific prospective evaluation to define optimal site-tailored strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19939-w","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:35:04Z","timestamp":1781627704000},"page":"8438-8447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with Longer Survival in Selected Cases: A Systematic Review and Meta-analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"Aya","family":"Maekawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhui","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk Janine","family":"van Bodegraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"De Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Grochowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6824-4533","authenticated-orcid":false,"given":"Giovanni","family":"Marchegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"19939_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"19939_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. Lancet. 2025;405:1182\u2013202.","journal-title":"Lancet"},{"key":"19939_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamasurg.2024.2485","volume":"159","author":"S Crippa","year":"2024","unstructured":"Crippa S, Malleo G, Mazzaferro V, et al. Futility of up-front resection for anatomically resectable pancreatic cancer. JAMA Surg. 2024;159:1139\u201347.","journal-title":"JAMA Surg"},{"key":"19939_CR4","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.hpb.2018.12.002","volume":"21","author":"VP Groot","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, et al. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. HPB Oxford. 2019;21:998\u20131008.","journal-title":"HPB Oxford"},{"key":"19939_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267:936\u201345.","journal-title":"Ann Surg"},{"key":"19939_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.pan.2024.07.017","volume":"24","author":"M Brunner","year":"2024","unstructured":"Brunner M, Flessa M, Jacobsen A, et al. Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma: a retrospective analysis of 272 patients. Pancreatology. 2024;24:930\u20137.","journal-title":"Pancreatology"},{"key":"19939_CR7","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/bjs.11144","volume":"106","author":"YI Kim","year":"2019","unstructured":"Kim YI, Song KB, Lee YJ, et al. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg. 2019;106:898\u2013909.","journal-title":"Br J Surg"},{"key":"19939_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12885-019-5630-4","volume":"19","author":"OB Gbolahan","year":"2019","unstructured":"Gbolahan OB, Tong Y, Sehdev A, O\u2019Neil B, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer. 2019;19:468.","journal-title":"BMC Cancer"},{"key":"19939_CR9","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3390\/jcm14041167","volume":"14","author":"A Mauro","year":"2025","unstructured":"Mauro A, Faverio C, Brizzi L, et al. Multidisciplinary therapeutic approaches to pancreatic cancer according to the resectability status. J Clin Med. 2025;14:1167.","journal-title":"J Clin Med"},{"key":"19939_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm14041129","volume":"14","author":"U Hayat","year":"2025","unstructured":"Hayat U, Croce PS, Saadeh A, et al. Current and emerging treatment options for pancreatic cancer: a comprehensive review. J Clin Med. 2025;14:1129.","journal-title":"J Clin Med"},{"key":"19939_CR11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"19939_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","volume":"34","author":"T Conroy","year":"2023","unstructured":"Conroy T, Pfeiffer P, Vilgrain V, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2023;34:987\u20131002.","journal-title":"Ann Oncol"},{"key":"19939_CR13","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38:3217\u201330.","journal-title":"J Clin Oncol"},{"key":"19939_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:439\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"19939_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M, et al. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28:493\u2013511.","journal-title":"Int J Clin Oncol"},{"key":"19939_CR16","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.ejso.2016.06.398","volume":"42","author":"S Crippa","year":"2016","unstructured":"Crippa S, Bittoni A, Sebastiani E, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"19939_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.pan.2023.07.005","volume":"23","author":"D Hashimoto","year":"2023","unstructured":"Hashimoto D, Satoi S, Fujii T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto. Pancreatology. 2023;23:682\u20138.","journal-title":"Pancreatology"},{"key":"19939_CR18","doi-asserted-by":"publisher","first-page":"109635","DOI":"10.1016\/j.ejso.2025.109635","volume":"51","author":"A Maekawa","year":"2025","unstructured":"Maekawa A, Omiya K, Oba A, et al. Clinical implications of disappearing pancreatic cancer liver metastases: lessons from colorectal liver metastases. Eur J Surg Oncol. 2025;51:109635.","journal-title":"Eur J Surg Oncol"},{"key":"19939_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1186\/s12885-022-10130-4","volume":"22","author":"L Miotke","year":"2022","unstructured":"Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I. Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real-world study. BMC Cancer. 2022;22:1054.","journal-title":"BMC Cancer"},{"key":"19939_CR20","doi-asserted-by":"publisher","first-page":"e017249","DOI":"10.1136\/bmjopen-2017-017249","volume":"8","author":"JC Lee","year":"2018","unstructured":"Lee JC, Ahn S, Cho IK, Lee J, Kim J, Hwang JH. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. BMJ Open. 2018;8:e017249.","journal-title":"BMJ Open"},{"key":"19939_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/cancers11070991","volume":"11","author":"L Moletta","year":"2019","unstructured":"Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C. Surgery for recurrent pancreatic cancer: is it effective? Cancers Basel. 2019;11:991.","journal-title":"Cancers Basel"},{"key":"19939_CR22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/cancers13061277","volume":"13","author":"S Serafini","year":"2021","unstructured":"Serafini S, Sperti C, Friziero A, et al. Systematic review and meta-analysis of surgical treatment for isolated local recurrence of pancreatic cancer. Cancers Basel. 2021;13:1277.","journal-title":"Cancers Basel"},{"key":"19939_CR23","doi-asserted-by":"publisher","first-page":"102067","DOI":"10.1016\/j.esmoop.2023.102067","volume":"8","author":"CS Leonhardt","year":"2023","unstructured":"Leonhardt CS, Stamm T, Hank T, Prager G, Strobel O. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open. 2023;8:102067.","journal-title":"ESMO Open"},{"key":"19939_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"19939_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","volume":"156","author":"BS Brooke","year":"2021","unstructured":"Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg. 2021;156:787\u20138.","journal-title":"JAMA Surg"},{"key":"19939_CR26","unstructured":"A. R. WebPlotDigitizer. 2024; Version 5.2. https:\/\/automeris.io."},{"key":"19939_CR27","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"19939_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361.","journal-title":"Res Synth Methods"},{"key":"19939_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.suronc.2020.08.005","volume":"35","author":"C Schwarz","year":"2020","unstructured":"Schwarz C, Fitschek F, Primavesi F, et al. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol. 2020;35:169\u201373.","journal-title":"Surg Oncol"},{"key":"19939_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12957-020-02058-5","volume":"18","author":"Y Mitsuka","year":"2020","unstructured":"Mitsuka Y, Yamazaki S, Yoshida N, Yan M, Higaki T, Takayama T. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol. 2020;18:294.","journal-title":"World J Surg Oncol"},{"key":"19939_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00423-023-03009-w","volume":"408","author":"Y Shibata","year":"2023","unstructured":"Shibata Y, Uemura K, Sumiyoshi T, et al. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg. 2023;408:280.","journal-title":"Langenbecks Arch Surg"},{"key":"19939_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3349\/ymj.2024.0078","volume":"66","author":"JH Kim","year":"2025","unstructured":"Kim JH, Hong SS, Kim SH, Hwang HK, Kang CM. Is there a potential oncologic role for local therapy on hepatic metastasis in patients who undergo curative pancreatectomy for pancreatic cancer? Yonsei Med J. 2025;66:329\u201336.","journal-title":"Yonsei Med J"},{"key":"19939_CR33","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3348\/kjr.2019.0647","volume":"21","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Kim JH, Kim SY, Won HJ, Shin YM, Kim PN. Percutaneous radiofrequency ablation for metachronous hepatic metastases after curative resection of pancreatic adenocarcinoma. Korean J Radiol. 2020;21:316\u201324.","journal-title":"Korean J Radiol"},{"key":"19939_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12032-023-02065-y","volume":"40","author":"C Wang","year":"2023","unstructured":"Wang C, Song L, Wang Z, Wang W. The application of radiofrequency ablation in pancreatic cancer liver-only recurrence after radical pancreatectomy. Med Oncol. 2023;40:209.","journal-title":"Med Oncol"},{"key":"19939_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pan.2019.11.015","volume":"20","author":"H Kurahara","year":"2020","unstructured":"Kurahara H, Maemura K, Mataki Y, et al. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer. Pancreatology. 2020;20:89\u201394.","journal-title":"Pancreatology"},{"key":"19939_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12893-021-01082-w","volume":"21","author":"SA Safi","year":"2021","unstructured":"Safi SA, Lehwald-Tywuschik N, Rehders A, et al. Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy. BMC Surg. 2021;21:110.","journal-title":"BMC Surg"},{"key":"19939_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12893-021-01236-w","volume":"21","author":"T Mashiko","year":"2021","unstructured":"Mashiko T, Nakano A, Masuoka Y, Yamamoto S, Ozawa S, Nakagohri T. Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Surg. 2021;21:237.","journal-title":"BMC Surg"},{"key":"19939_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/jhbp.1127","volume":"29","author":"Y Homma","year":"2022","unstructured":"Homma Y, Endo I, Matsuyama R, et al. Outcomes of lung metastasis from pancreatic cancer: a nationwide multicenter analysis. J Hepatobiliary Pancreat Sci. 2022;29:552\u201361.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"19939_CR39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.surg.2023.05.008","volume":"174","author":"CM Stuart","year":"2023","unstructured":"Stuart CM, Kirsch MJ, Zhuang Y, et al. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Surgery. 2023;174:654\u20139.","journal-title":"Surgery"},{"key":"19939_CR40","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s11605-011-1605-8","volume":"15","author":"GJ Arnaoutakis","year":"2011","unstructured":"Arnaoutakis GJ, Rangachari D, Laheru DA, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15:1611\u20137.","journal-title":"J Gastrointest Surg"},{"key":"19939_CR41","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.pan.2020.08.019","volume":"20","author":"H Otsuka","year":"2020","unstructured":"Otsuka H, Uemura K, Kondo N, et al. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Pancreatology. 2020;20:1472\u20138.","journal-title":"Pancreatology"},{"key":"19939_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00595-019-01902-w","volume":"50","author":"T Shimizu","year":"2020","unstructured":"Shimizu T, Taniguchi K, Asakuma M, et al. Initial pulmonary metastasis after pancreatectomy for pancreatic ductal adenocarcinoma. Surg Today. 2020;50:413\u20138.","journal-title":"Surg Today"},{"key":"19939_CR43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.suronc.2019.08.010","volume":"31","author":"M Ilmer","year":"2019","unstructured":"Ilmer M, Schiergens TS, Renz BW, et al. Oligometastatic pulmonary metastasis in pancreatic cancer patients: safety and outcome of resection. Surg Oncol. 2019;31:16\u201321.","journal-title":"Surg Oncol"},{"key":"19939_CR44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1245\/s10434-012-2762-z","volume":"20","author":"O Strobel","year":"2013","unstructured":"Strobel O, Hartwig W, Hackert T, et al. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964\u201372.","journal-title":"Ann Surg Oncol"},{"key":"19939_CR45","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.surg.2018.05.050","volume":"164","author":"S Yamada","year":"2018","unstructured":"Yamada S, Kobayashi A, Nakamori S, et al. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery. 2018;164:1049\u201356.","journal-title":"Surgery"},{"key":"19939_CR46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ejso.2016.12.012","volume":"43","author":"T Comito","year":"2017","unstructured":"Comito T, Cozzi L, Zerbi A, et al. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: a retrospective study. Eur J Surg Oncol. 2017;43:735\u201342.","journal-title":"Eur J Surg Oncol"},{"key":"19939_CR47","doi-asserted-by":"publisher","first-page":"100818","DOI":"10.1016\/j.tranon.2020.100818","volume":"13","author":"J Li","year":"2020","unstructured":"Li J, Wang Z, Li AM, Zhou H, Zhu XX. Analysis of the efficacy, safety, and survival factors of stereotactic body radiation therapy in patients with recurrence of pancreatic cancer. Transl Oncol. 2020;13:100818.","journal-title":"Transl Oncol"},{"key":"19939_CR48","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.21037\/jgo-22-38","volume":"13","author":"AV Reddy","year":"2022","unstructured":"Reddy AV, Hill CS, Sehgal S, et al. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. J Gastrointest Oncol. 2022;13:1402\u201312.","journal-title":"J Gastrointest Oncol"},{"key":"19939_CR49","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.pan.2025.04.012","volume":"25","author":"K Yamane","year":"2025","unstructured":"Yamane K, Morino K, Anazawa T, et al. Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: a stratified analysis of locoregional treatment benefits. Pancreatology. 2025;25:889\u201397.","journal-title":"Pancreatology"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19939-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:49:15Z","timestamp":1786204155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19939-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19939"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19939-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}